Azithromycin targets bacterial protein synthesis. Specifically, it binds to the 50S ribosomal subunit of Neisseria gonorrhoeae (gonorrhea) and Chlamydia trachomatis (chlamydia), preventing peptide chain elongation. This blockage halts bacterial protein production, ultimately leading to bacterial cell death.
In gonorrhea, azithromycin’s effectiveness is somewhat limited due to increasing resistance. Therefore, it’s often used in combination with ceftriaxone. However, azithromycin remains a valuable option for treating chlamydia infections, demonstrating higher efficacy against this organism. Its prolonged half-life allows for once-daily dosing, improving patient compliance.
The mechanism’s success depends on the concentration of azithromycin reaching the infection site. Factors like bacterial resistance mechanisms and host immune response influence treatment outcome. While generally well-tolerated, side effects such as gastrointestinal upset can occur.
Always consult a healthcare professional for accurate diagnosis and appropriate treatment. Self-treating sexually transmitted infections is risky and can lead to treatment failure and complications.
